Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR⁻/⁻ mice

Date
2012-07-29Author
Murali, Ganesan
Milne, Ginger L.
Webb, Corey D.
Stewart, Ann B.
McMillan, Ryan P.
Lyle, Brandon C.
Hulver, Matthew W.
Saraswathi, Viswanathan
Metadata
Show full item recordAbstract
Fish oil (FO) is a potent anti-inflammatory and lipid-lowering agent. Because inflammation can modulate lipid metabolism and vice versa, we hypothesized that combining FO with cyclooxygenase inhibitors (COXIBs), well-known anti-infl ammatory drugs, can enhance the antiinfl ammatory and lipid-lowering effect of FO. LDLR⁻/⁻ mice were fed a high-fat diet supplemented with 6% olive oil or FO for 12 wk in the presence or absence of indomethacin (Indo, 6 mg/l drinking water). FO reduced plasma total cholesterol by 30% but, in combination with Indo, exerted a greater decrease (44%). The reduction of liver cholesterol ester (CE) and triglycerides (TG) by FO (63% and 41%, respectively) was enhanced by Indo (80% in CE and 64% in TG). FO + Indo greatly increased the expression of genes modulating lipid metabolism and reduced the expression of inflammatory genes compared with control. The mRNA and/or protein expression of pregnane X receptor (PXR) and cytochrome P450 isoforms that alter inflammation and/or lipid metabolism are increased to a greater extent in mice that received FO + Indo. Moreover, the nuclear level of PXR is significantly increased in FO + Indo group. Combining FO with COXIBs may exert their beneficial effects on inflammation and lipid metabolism via PXR and cytochrome P450.